Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $1.2 in the prior trading day, Fate Therapeutics Inc (NASDAQ: FATE) closed at $1.14, down -5.00%. In other words, the price has decreased by -$5.00 from its previous closing price. On the day, 2.11 million shares were traded. FATE stock price reached its highest trading level at $1.19 during the session, while it also had its lowest trading level at $1.06.
Ratios:
Our goal is to gain a better understanding of FATE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.04 and its Current Ratio is at 8.04. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.29.
On June 17, 2024, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $4 to $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 04 ’25 when TAHL CINDY sold 9,037 shares for $1.06 per share. The transaction valued at 9,573 led to the insider holds 397,670 shares of the business.
Valamehr Bahram sold 14,466 shares of FATE for $15,396 on Aug 04 ’25. The President and CEO now owns 334,898 shares after completing the transaction at $1.06 per share. On Aug 04 ’25, another insider, TAHL CINDY, who serves as the Officer of the company, bought 9,037 shares for $1.06 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 131476200 and an Enterprise Value of -10020145. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.52 while its Price-to-Book (P/B) ratio in mrq is 0.50. Its current Enterprise Value per Revenue stands at -1.183 whereas that against EBITDA is 0.062.
Stock Price History:
The Beta on a monthly basis for FATE is 2.22, which has changed by -0.7084399 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, FATE has reached a high of $4.20, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -2.03%, while the 200-Day Moving Average is calculated to be -19.09%.
Shares Statistics:
The stock has traded on average 1.72M shares per day over the past 3-months and 1787900 shares per day over the last 10 days, according to various share statistics. A total of 114.66M shares are outstanding, with a floating share count of 109.47M. Insiders hold about 5.08% of the company’s shares, while institutions hold 70.49% stake in the company. Shares short for FATE as of 1753920000 were 9279254 with a Short Ratio of 5.41, compared to 1751241600 on 9544385. Therefore, it implies a Short% of Shares Outstanding of 9279254 and a Short% of Float of 9.24.
Earnings Estimates
The firm’s stock currently is rated by 10.0 analysts. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.08 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$0.66 and -$1.37 for the fiscal current year, implying an average EPS of -$1.11. EPS for the following year is -$1.03, with 10.0 analysts recommending between -$0.31 and -$1.46.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for FATE’s current fiscal year. The highest revenue estimate was $13.6M, while the lowest revenue estimate was $3.54M, resulting in an average revenue estimate of $7.03M. In the same quarter a year ago, actual revenue was $13.63M
